Contemporary Outcomes of High Risk Relapsed Refractory Classical Hodgkin Lymphoma Patients-role of Maintenance Therapy in the Real World
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Schmitz N, Pfistner B, Sextro M, Sieber M, Carella A, Haenel M
. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002; 359(9323):2065-71.
DOI: 10.1016/S0140-6736(02)08938-9.
View
2.
Devillier R, Coso D, Castagna L, Brenot Rossi I, Anastasia A, Chiti A
. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Haematologica. 2012; 97(7):1073-9.
PMC: 3396680.
DOI: 10.3324/haematol.2011.056051.
View
3.
Moskowitz C, Matasar M, Zelenetz A, Nimer S, Gerecitano J, Hamlin P
. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2011; 119(7):1665-70.
PMC: 3790950.
DOI: 10.1182/blood-2011-10-388058.
View
4.
Moskowitz C, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J
. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018; 132(25):2639-2642.
DOI: 10.1182/blood-2018-07-861641.
View
5.
Schot B, Zijlstra J, Sluiter W, van Imhoff G, Pruim J, Vaalburg W
. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood. 2006; 109(2):486-91.
DOI: 10.1182/blood-2005-11-006957.
View